AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34695525 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1844
Study 34695615 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-day intraprostatic fiducial marker placement, perirectal hydrogel injection, and CT and MRI simulation
Number of subjects: 21
Study 34696602 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34696666 — intervention group
Group type: EXPERIMENTAL
Intervention: EIBI/APERS-P-SE preschools
Number of subjects: 0
Study 34696666 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34696785 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-delivered cognitive behavioral therapy (iCBT) program combined with exercise therapy and education
Number of subjects: 0
Study 34696785 — intervention group
Group type: COMPARATOR
Intervention: exercise therapy and education
Number of subjects: 0
Study 34696816 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious game training for iER skills
Number of subjects: 0
Study 34696816 — intervention group
Group type: COMPARATOR
Intervention: Control group playing a game without psychoeducational content
Number of subjects: 0
Study 34697109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 200
Study 34697109 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin overlapped with warfarin
Number of subjects: 200
Study 34697111 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of peg-IFN alpha 180 µg per week for 48 weeks combined with oral TDF 300 mg daily
Number of subjects: 272
Study 34697111 — intervention group
Group type: COMPARATOR
Intervention: TDF monotherapy 300 mg oral daily
Number of subjects: 272
Study 34697123 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPASS (digital cognitive-behavioural therapy programme) with six therapist contacts over 10 weeks
Number of subjects: 200
Study 34697123 — intervention group
Group type: COMPARATOR
Intervention: Standard charity support (SCS)
Number of subjects: 200
Study 34697125 — intervention group
Group type: EXPERIMENTAL
Intervention: Live image-guided lead placement
Number of subjects: 130
Study 34697125 — intervention group
Group type: COMPARATOR
Intervention: Empirical lead placement
Number of subjects: 130
Study 34697911 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated program including 'ad hoc' transportation and fast-track access to care; 12-week sofosbuvir/velpatasvir regimen without Ribavirin.
Number of subjects: 1470
Study 34697911 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and linkage to care improvements through a PWUD-tailored service.
Number of subjects: 1470
Study 34699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Aseptic technique
Number of subjects: 1339
Study 34699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-use (sterile) catheter
Number of subjects: 1339
Study 34699062 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated catheters
Number of subjects: 1339
Study 34699069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponatinib
Number of subjects: 260
Study 34699288 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) imaging
Number of subjects: 0
Study 34699288 — intervention group
Group type: COMPARATOR
Intervention: Standard CT imaging
Number of subjects: 0
Study 34699302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported ICS and SABA use
Number of subjects: 100
Study 34699302 — intervention group
Group type: COMPARATOR
Intervention: Objective ICS adherence and SABA use
Number of subjects: 100
Study 34699302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported ICS usage
Number of subjects: 100
Study 34699302 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medication monitors (EMMs)
Number of subjects: 100
Study 34699592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel) at 50 × 106 or 100 × 106 CAR+ T cells
Number of subjects: 25
Study 34699592 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 25
Study 34699735 — intervention group
Group type: EXPERIMENTAL
Intervention: Bean-rich diet (0.3 cups beans/day) for 8 weeks
Number of subjects: 54
Study 34699735 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 54
Study 34699945 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) interventions
Number of subjects: 2000
Study 34700344 — intervention group
Group type: EXPERIMENTAL
Intervention: VEN 200 mg and IBR 420 mg
Number of subjects: 35
Study 34700344 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms (including various dosing combinations)
Number of subjects: 35
Study 34700344 — intervention group
Group type: COMPARATOR
Intervention: Higher dosing combinations (IBR 560 mg and VEN 400 mg)
Number of subjects: 35
Study 34700343 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced intensity conditioning (RIC) double umbilical cord blood transplantation (DUCBT)
Number of subjects: 58
Study 34700343 — intervention group
Group type: EXPERIMENTAL
Intervention: Chimerism patterns observed after DUCBT
Number of subjects: 58
Study 34702062 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Number of subjects: 215
Study 34702064 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (target SBP, 130-140 mm Hg)
Number of subjects: 4511
Study 34702064 — intervention group
Group type: COMPARATOR
Intervention: Guideline-recommended treatment (target SBP <180 mm Hg)
Number of subjects: 4511
Study 34702087 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34702124 — intervention group
Group type: EXPERIMENTAL
Intervention: VARIVAX™ 0.5 mL (1 dose for ages 12 months-12 years; 2 doses 6 weeks apart for ages 13-17 years)
Number of subjects: 100
Study 34702229 — intervention group
Group type: EXPERIMENTAL
Intervention: WelTel mobile health platform
Number of subjects: 51
Study 34702317 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation (4x1 anodal HD-tDCS montage, 2 mA, 20 min) during VRT sessions
Number of subjects: 58
Study 34702317 — intervention group
Group type: COMPARATOR
Intervention: Active sham stimulation (2 mA, 30 s) during VRT sessions
Number of subjects: 58
Study 34702317 — intervention group
Group type: EXPERIMENTAL
Intervention: Real stimulation
Number of subjects: 58
Study 34702317 — intervention group
Group type: COMPARATOR
Intervention: Active sham stimulation
Number of subjects: 58
Study 34702336 — intervention group
Group type: EXPERIMENTAL
Intervention: TAPER (Team Approach to Polypharmacy Evaluation and Reduction)
Number of subjects: 360
Study 34702336 — intervention group
Group type: COMPARATOR
Intervention: Control (wait list)
Number of subjects: 360
Study 34702567 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigil
Number of subjects: 45
Study 34702567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: DICA 1
Number of subjects: 2215
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: DICA 2
Number of subjects: 2215
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: DICA 3
Number of subjects: 2215
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: CODA A
Number of subjects: 2215
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: CODA B
Number of subjects: 2215
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: CODA C
Number of subjects: 2215
Study 34702716 — intervention group
Group type: EXPERIMENTAL
Intervention: CODA score
Number of subjects: 2215
Study 34702747 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forests (RF) model
Number of subjects: 15465
Study 34702747 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Boosting Machine
Number of subjects: 15465
Study 34702747 — intervention group
Group type: EXPERIMENTAL
Intervention: Extreme Gradient Boosting
Number of subjects: 15465
Study 34702747 — intervention group
Group type: COMPARATOR
Intervention: NIHSS
Number of subjects: 15465
Study 34702811 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab 200 mg intravenously every 3 weeks for up to 24 months
Number of subjects: 28
Study 34702811 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab
Number of subjects: 28
Study 34702867 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-LAMP assay (EasyCoV) in saliva
Number of subjects: 1718
Study 34702867 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva RT-LAMP
Number of subjects: 1718
Study 34702867 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal RT-PCR
Number of subjects: 1718
Study 34702867 — intervention group
Group type: COMPARATOR
Intervention: Saliva RT-PCR
Number of subjects: 1718
Study 34702867 — intervention group
Group type: COMPARATOR
Intervention: Nasopharyngeal antigen testing
Number of subjects: 1718
Study 34702956 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirtuin 6 (SIRT6) overexpression
Number of subjects: 0
Study 34702956 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid treatment
Number of subjects: 0
Study 34702956 — intervention group
Group type: EXPERIMENTAL
Intervention: KLF10/SIRT6 signaling activation
Number of subjects: 0
Study 34702956 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic or pharmacological manipulation in KLF10-depleted PDAC cells
Number of subjects: 0
Study 34702956 — intervention group
Group type: COMPARATOR
Intervention: KLF10 deficiency
Number of subjects: 0
Study 34703348 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihemophilic factor (recombinant) (rAHF; ADVATE) prophylaxis
Number of subjects: 54
Study 34703985 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable circulating cell-free DNA (cfDNA) in advanced melanoma patients
Number of subjects: 149
Study 34704389 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin/relebactam (IMI/REL)
Number of subjects: 0
Study 34704389 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin/tazobactam
Number of subjects: 0
Study 34704959 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-component BE-EHR module intervention + standard care
Number of subjects: 66
Study 34704959 — intervention group
Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 66
Study 34704958 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1, 3, and 12 months after study inclusion
Number of subjects: 1700
Study 34704958 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 3 and 12 months
Number of subjects: 1700
Study 34704958 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 1 year
Number of subjects: 1700
Study 34704958 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up during the first 3 months after inclusion
Number of subjects: 1700
Study 34705736 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline distress measured by the Traumatic Injuries Distress Scale (TIDS)
Number of subjects: 116
Study 34705736 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of baseline distress (TIDS score)
Number of subjects: 116
Study 34705736 — intervention group
Group type: EXPERIMENTAL
Intervention: TIDS score of 5
Number of subjects: 116
Study 34705736 — intervention group
Group type: EXPERIMENTAL
Intervention: TIDS score of 13
Number of subjects: 116
Study 34706161 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzagliatin
Number of subjects: 0
Study 34706553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention for intermittent claudication (IC)
Number of subjects: 3326
Study 34706553 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular intervention for critical limb ischemia (CLI)
Number of subjects: 3326
Study 34706564 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Number of subjects: 4029
Study 34706691 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychodynamic therapy (PDT)
Number of subjects: 22
Study 34706691 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 22
Study 34706698 — intervention group
Group type: EXPERIMENTAL
Intervention: First 1000 Days Program
Number of subjects: 264
Study 34706710 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-Body Skills Groups (MBSGs)
Number of subjects: 39
Study 34706764 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II Retinal Prosthesis System
Number of subjects: 10
Study 34706777 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month complex lifestyle intervention program including instructor-led high-intensive exercise and nutritionist- and psychologist-led counselling
Number of subjects: 16
Study 34706777 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month complex lifestyle intervention program
Number of subjects: 16
Study 34706874 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (any dose)
Number of subjects: 3770
Study 34706874 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (2 mg or 4 mg)
Number of subjects: 3770
Study 34706885 — intervention group
Group type: EXPERIMENTAL
Intervention: HIC-H patients treated with ICI regimens (n=196)
Number of subjects: 3570
Study 34706885 — intervention group
Group type: COMPARATOR
Intervention: HIC-C patients treated with ICI regimens (n=88)
Number of subjects: 3570
Study 34706885 — intervention group
Group type: EXPERIMENTAL
Intervention: HIC-H patients treated with ICI monotherapy
Number of subjects: 3570
Study 34706885 — intervention group
Group type: COMPARATOR
Intervention: HIC-C patients treated with ICI monotherapy
Number of subjects: 3570
Study 34706885 — intervention group
Group type: EXPERIMENTAL
Intervention: HIC-H patients treated with ICI plus chemotherapy
Number of subjects: 3570
Study 34706885 — intervention group
Group type: COMPARATOR
Intervention: HIC-C patients treated with ICI plus chemotherapy
Number of subjects: 3570
Study 34706884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioversion (both direct current and pharmacological)
Number of subjects: 52057
Study 34706884 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct current cardioversion
Number of subjects: 52057
Study 34706884 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion
Number of subjects: 52057
Study 34706884 — intervention group
Group type: COMPARATOR
Intervention: No cardioversion
Number of subjects: 52057
Study 34706963 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate single blastocyst transfer in mNC-FET
Number of subjects: 464
Study 34706963 — intervention group
Group type: COMPARATOR
Intervention: Postponed single blastocyst transfer in mNC-FET
Number of subjects: 464
Study 34706967 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept conversion
Number of subjects: 446
Study 34706967 — intervention group
Group type: COMPARATOR
Intervention: CNI continuation
Number of subjects: 446
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant treatment
Number of subjects: 166
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotensive treatment
Number of subjects: 166
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 166
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory evaluations and vital signs
Number of subjects: 166
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity, corneal and conjunctival staining, and chemosis
Number of subjects: 166
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AE) incidence
Number of subjects: 166
Study 34707360 — intervention group
Group type: EXPERIMENTAL
Intervention: Lubricant and hypotensive investigational drugs
Number of subjects: 166
Study 34707489 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34708091 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxiris Membrane
Number of subjects: 0
Study 34708091 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study 34708171 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic machine perfusion (NMP) for 120 minutes at 37 degrees Celsius
Number of subjects: 80
Study 34708171 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic machine perfusion (HMP) alone
Number of subjects: 80
Study 34708217 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor rate of force development (RFD) early (0-50 ms)
Number of subjects: 13
Study 34708217 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee extensor rate of force development (RFD) late (100-200 ms)
Number of subjects: 13
Study 34708217 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal voluntary force (MVF) adjusted for body weight
Number of subjects: 13
Study 34708297 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC2A1 HaeIII and HpyCH4V SNPs
Number of subjects: 342
Study 34708399 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine (CBM)
Number of subjects: 0
Study 34708399 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC, dronabinol)
Number of subjects: 0
Study 34708399 — intervention group
Group type: EXPERIMENTAL
Intervention: Lu AG06466 (formerly known as ABX-1431)
Number of subjects: 0
Study 34709196 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (intervention group, n=220 patients)
Number of subjects: 330
Study 34709196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group, n=110 patients)
Number of subjects: 330
Study 34709196 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (intervention group)
Number of subjects: 330
Study 34709196 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 330
Study 34709196 — intervention group
Group type: EXPERIMENTAL
Intervention: Interprofessional collaboration and quality of interprofessional shared decision making (measured with clinicians)
Number of subjects: 330
Study 34709529 — intervention group
Group type: EXPERIMENTAL
Intervention: Very hard physical activity
Number of subjects: 54
Study 34709529 — intervention group
Group type: EXPERIMENTAL
Intervention: Total time of moderate to very hard physical activity
Number of subjects: 54
Study 34709529 — intervention group
Group type: EXPERIMENTAL
Intervention: Total caloric intake
Number of subjects: 54
Study 34709605 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Number of subjects: 566
Study 34709605 — intervention group
Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 566
Study 34709814 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986278
Number of subjects: 0
Study 34709814 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34710334 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based program focused on youth academic success
Number of subjects: 0
Study 34710362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine and non-coated suture
Number of subjects: 5788
Study 34710362 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% alcoholic chlorhexidine and triclosan-coated suture
Number of subjects: 5788
Study 34710362 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% aqueous povidone-iodine and non-coated suture
Number of subjects: 5788
Study 34710362 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% aqueous povidone-iodine and triclosan-coated suture
Number of subjects: 5788
Study 34710362 — intervention group
Group type: COMPARATOR
Intervention: 2% alcoholic chlorhexidine
Number of subjects: 5788
Study 34710362 — intervention group
Group type: COMPARATOR
Intervention: Triclosan-coated sutures
Number of subjects: 5788
Study 34711141 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0
Study 34711167 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantra® system (QPlus® Cartridge)
Number of subjects: 38
Study 34711167 — intervention group
Group type: COMPARATOR
Intervention: ROTEM® sigma (ROTEM® sigma complete + hep Cartridge)
Number of subjects: 38
Study 34711189 — intervention group
Group type: EXPERIMENTAL
Intervention: MALDI-TOF spectra analysis
Number of subjects: 0
Study 34711210 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting of incidental findings (IFs) of severe structural abnormalities
Number of subjects: 8252
Study 34711210 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of IFs to participants
Number of subjects: 8252
Study 34711210 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of IFs
Number of subjects: 8252
Study 34711210 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participant perception of the study
Number of subjects: 8252
Study 34711210 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of the restricted approach to IF management
Number of subjects: 8252
Study 34711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 0
Study 34711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider capability to prescribe low-value ADT
Number of subjects: 0
Study 34711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider opportunity to prescribe low-value ADT
Number of subjects: 0
Study 34711274 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider motivation regarding ADT use
Number of subjects: 0
Study 34711394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER)
Number of subjects: 37475
Study 34711394 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 37475
Study 34711430 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER)
Number of subjects: 37475
Study 34711430 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve replacement (TMVR)
Number of subjects: 37475
Study 34711577 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON test positive patients receiving antituberculosis treatment (ATT) for 6 months
Number of subjects: 1075
Study 34711577 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON test value >2 IU/mL
Number of subjects: 1075
Study 34711577 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON test threshold of 4 IU/mL
Number of subjects: 1075
Study 34711597 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower SpO2 targets during mechanical ventilation
Number of subjects: 0
Study 34711597 — intervention group
Group type: COMPARATOR
Intervention: Standard SpO2 targets during mechanical ventilation
Number of subjects: 0